DO US MANAGED CARE ORGANIZATIONS RESTRICT COVERAGE MORE THAN THE FOOD AND DRUG ADMINISTRATION LABEL?

被引：0
|
作者：
Da Conceicao, R. [1 ]
Narvekar, P. [1 ]
Okorozo, P. [2 ]
机构：
[1] Avalere Hlth, New York, NY USA
[2] Avalere Hlth, Buffalo, NY USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HPR116
引用
收藏
页码：S214 / S215
页数：2
相关论文
共 50 条
  • [1] US Food and Drug Administration Regulations and Birth Defect Prevention: It's More Than Labeling
    Johnson, T. N.
    BIRTH DEFECTS RESEARCH, 2018, 110 (09): : 737 - 737
  • [2] Managed care formularies do restrict opportunities to individualize care ... but present an option to control drug costs
    Wilson, E
    FORMULARY, 1995, 30 (12) : 815 - 816
  • [3] Citizens Urge US Food and Drug Administration to Restrict High-Potency Opioids
    Kolcun, John Paul G.
    Madhavan, Karthik
    Wang, Michael Y.
    WORLD NEUROSURGERY, 2017, 108 : 959 - 960
  • [4] What Is US Food and Drug Administration Looking for to Assess and Label Risk?
    Taylor, L. G.
    BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2016, 106 (05) : 382 - 382
  • [5] US Food and Drug Administration regulations governing label claims for food products, including probiotics
    Saldanha, Leila G.
    CLINICAL INFECTIOUS DISEASES, 2008, 46 : S119 - S121
  • [6] Time From Authorization by the US Food and Drug Administration to Medicare Coverage for Novel Technologies
    Sexton, Zachary A.
    Perl, Juliana R.
    Saul, Henry R.
    Trotsyuk, Artem A.
    Pietzsch, Jan B.
    Ruggles, Sandra Waugh
    Nikolov, Margaret C.
    Schulman, Kevin A.
    Makower, Josh
    JAMA HEALTH FORUM, 2023, 4 (08): : E232260
  • [7] Utility of a US Food and Drug Administration (FDA) label indication for condoms for anal sex
    Siegler, Aaron J.
    Ahlschlager, Lauren
    Rosenthal, Elizabeth M.
    Sullivan, Patrick S.
    Kelley, Colleen F.
    Rosenberg, Eli S.
    Sanchez, Travis H.
    Moore, Renee H.
    Mehta, C. Christina
    Cecil, Michael P.
    SEXUAL HEALTH, 2020, 17 (01) : 91 - 95
  • [8] Promotion of Drugs for Off-label Uses The US Food and Drug Administration at a Crossroads
    Kim, Jeanie
    Kapczynski, Amy
    JAMA INTERNAL MEDICINE, 2017, 177 (02) : 157 - 158
  • [9] Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
    Cherla, Avi
    Naci, Huseyin
    Kesselheim, Aaron S.
    Gyawali, Bishal
    Mossialos, Elias
    JAMA INTERNAL MEDICINE, 2021, 181 (04) : 490 - 498
  • [10] Evaluation of US Food and Drug Administration Drug Label Recommendations for Coadministration of Antivirals and Acid-Reducing Agents
    Shugg, Tyler
    Powell, Nicholas R.
    Marroum, Patrick J.
    Skaar, Todd C.
    Younis, Islam R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (05) : 1088 - 1097
12345